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1. Introduction 
Cancer is a life-threatening disease, not as a result of the primary tumor that can be removed 
surgically in the vast majority of cases but from its metastatic spread to distant parts of the 
body. These metastases are often seen as a hopeless end-stage of the cancer disease and at 
this time only palliative treatments are applied. Some of the most prevalent solid tumors, 
such as breast-, lung- and prostate cancers, metastasize into the skeleton and cause either 
osteolytic (destructive) or osteoblastic lesions. Both types are often accompanied by bone 
pain and increased bone fragility and thus are reason for extended suffering. In breast 
cancer, bone is the site of first distant relapse and the clinical course of these women is 
relatively long, with a median survival of 2-3 years (1, 2). Lytic skeletal metastases are 
present in over 90% of patients who die from breast cancer (3).  
Many factors are involved in the pathogenesis of lytic skeletal lesions among which the 
proteins osteopontin (OPN) and bone sialoprotein II (BSPII) are considered to play an 
important role. In patients with primary breast cancer, elevated serum BSPII was recognized 
as prognostic marker of subsequent bone metastasis and was associated with poor survival 
(4-8). BSPII is a noncollagenous protein of the extracellular bone matrix and a member of the 
SIBLING (Small Integrin-Binding Ligand, N-linked Glycoprotein) family. The SIBLINGs are 
mainly clustered on human chromosome 4, and include bone sialoprotein II, osteopontin, 
dentin matrix protein 1 (DMP1), matrix extracellular phosphoglycoprotein (MEPE) and 
dentin sialophosphoprotein (DSPP) (12). These proteins are normally expressed in 
mineralizing tissues of bone and teeth but are also found in different cancers (13). In normal 
bone, BSPII is expressed by osteoblasts, osteoclasts and other skeleton-associated cell types, 
especially at sites of new mineral formation (12, 14-16). In this case, BSPII is a potential 
nucleator of hydroxyapatite formation and a specific marker of osteoblast differentiation 
(14). The sialoprotein is involved in hydroxyapatite and collagen binding, as well as in the 
attachment of bone cells including fibroblasts, osteoblasts and osteoclasts to solid surfaces, 
                                                 
* Tobias J. Bäuerle1, Victoria Elazar2, Jenny Peterschmitt1, Rinat Lifshitz-Shovali2, Hassan Adwan1,  
Franz P. Armbruster3, Gershon Golomb2 and Martin R. Berger1 
1Unit of Chemotherapy & Toxicology, German Cancer Research Center, Heidelberg 
2School of Pharmacy, Faculty of Medicine, The Hebrew University of Jerusalem, Jerusalem 
3Immundiagnostik AG, Bensheim 
1,3Germany 
2Israel 
www.intechopen.com
 Breast Cancer – Current and Alternative Therapeutic Modalities 
 
454 
but they are also secreted by breast cancer cells and this presumably is related to their 
specific homing into osseous tissue (12, 14, 16-19). This fact as well as the interaction with 
molecules as factor H, integrins, and the ensuing stimulation of signaling cascades 
promoting migration led to consider BSPII as an important player in the pathogenesis of 
lytic skeletal lesions (18, 20). 
One of the other sibling proteins is osteopontin which is a secreted, adhesive non-collagenous 
phosphorylated glycoprotein. This molecule was found to be a metastasis-associated protein in 
human breast cancer in that over-expression of OPN in breast tumours as well as in blood of 
patients was highly correlated with tumour progression and bad prognosis (21, 22). OPN was 
initially described as a protein, the secretion of which was elevated in many transformed cells 
in culture (23). In addition, OPN can bind to a number of receptors such as integrins as well as 
to certain variant forms of CD44, and it can act as a cytokine (24-26). 
For further investigation of the functions from BSPII and OPN in the course of bone 
metastasis formation, we set up an animal model that would allow following processes such 
as tumor cell extravasation, adhesion to the target tissue (bone) and formation of osteolytic 
lesions. For this complex scenario, animal models are indispensable tools to investigate the 
pathogenesis of bone metastasis in vivo and to examine the effects of a therapeutic 
intervention. For inducing breast cancer bone metastasis in rodents, most experimental 
models require the injection of human cancer xenografts into immunodeficient mice. This is 
commonly achieved by intracardial injection or intraosseous administration of breast cancer 
cells (27). Disadvantageously, the former mode of tumor cell administration into the left 
ventricle of the heart is associated with dissemination of tumor cells into all skeletal and 
visceral peripheries of the organism. Local intraosseous administration, however, causes 
bone damage and lacks processes such as tumor cell extravasation and invasion. Finally, 
methods based on the injection of bone specific tumor cell subclones are more likely to 
specifically induce and mimic the process of bone metastasis, but metastatic dissemination is 
still observed at multiple skeletal sites. 
Here we describe a new experimental animal model for inducing site-specific osteolytic 
lesions in the hind leg of nude rats. This method is characterized by intra-arterial injection of 
human breast cancer cells into an anastomosing vessel between the femoral and the iliac 
arteries. This model can be applied to explore the effects of a drug against bone related 
tumors, which should result in a reduced growth of osteolytic lesions in the treated animals. 
2. In vivo metastasis model 
Nude rats (RNU strain) were obtained from Harlan Winkelmann (Borchen, Germany) or 
Charles River (Sulzfeld, Germany) at an age of 4–6 weeks. They were housed 4 per cage at 
specific pathogen-free conditions in a minibarrier system of the central animal facility. 
Autoclaved feed and water was given ad libitum to the animals that were maintained under 
controlled conditions (21 ± 2°C room temperature, 60% humidity, and 12 hour light-dark 
rhythm).  
Subconfluent human breast cancer cells (MDA-MB-231GFP+) were harvested using 2 mM 
EDTA in PBS- (phosphate-buffered saline without Ca2+ and Mg2+) and 0.25% trypsin. The 
cells were washed twice with PBS (with Ca2+ and Mg2+), subsequently counted and re-
suspended in PBS to a concentration of 5x105 cells per 1 ml. For tumor cell implantation, rats 
were anaesthetized with a mixture of laughing gas (nitrous oxide; 1 l/min), oxygen (0.5 
l/min) and isoflurane (1–1.5 vol. %). 
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The respective area of a rat’s hind leg was shaved and disinfected. A clear cut of 2–3 cm 
length was performed in the inguinal region (Fig. 1).  
 
 
Fig. 1. Shaved and desinfected rat thigh, prepared for tumor cell implantation - showing the 
first incision. 
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Fig. 2. The branching pattern of the femoral artery, photographed through an operation 
microscope (magnification 16-fold). 
After preparation of all arterial branches as seen in Figure 2, the flow of the femoral artery 
(FA; Fig. 2) was temporarily occluded by clips that were placed proximal and distal of the 
superficial epigastric artery’s (SEA; Fig. 2) origin. The deep femoral artery (Fig. 2), which 
normally branches off the FA thus supplying the medial and caudal muscles of the thigh, 
was also clipped in cases of an anatomical variant as seen in Figure 2. In addition, the SEA 
was ligated distally, which allowed the opening of this vessel without bleeding. In this 
context, it is interesting to note that a ligation of the distal SEA is possible because it 
anastomoses with the caudal epigastric artery that arises from the pudendoepigastric trunk, 
which is a branch of the iliac artery. After making an incision proximal of the ligation, a 1% 
papaverin solution was administered onto the SEA to facilitate the subsequent insertion of a 
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needle (0.3 mm diameter and 42 mm length). After insertion, the needle was fixed in an 
external support, which reduces irregular movements that would result in perforation of the 
arterial wall and allows connection with a syringe. Then the distal clip was removed from 
the FA and placed onto the saphenous artery, which runs superficially and supplies the 
dorsal and plantar aspects of the foot. MDA-MB-231GFP+ cells (105 cells suspended in 0.2 ml 
PBS) were slowly injected into the SEA and by virtue of the clips directed to the descending 
genicular and popliteal arteries (Fig. 2), both supplying the knee joint and muscles of the 
right hind leg. 
The growth of these tumor cells as well as the formation of lytic lesions was followed 
subsequently by radiographic examinations. The imaging of the rats was performed every 7 
– 14 days under general anesthesia. The animals were fixed in a.p. and p.a. position and 
exposed to X-rays. The X-ray films were processed by an automatic developing machine and 
the resulting images were scanned using a digital imaging program with a resolution of 300 
dpi. After inverting the scanned radiographs (turning positive into negative), analyses were 
done with a computer based imaging program. From the beginning to the end of this study, 
tumor growth and lytic lesions occurred exclusively in the femur, tibia and fibula of the 
respective hind leg (Fig. 3a). For a 3-dimensional volume rendering reconstructions of the 
skeleton we performed a high resolution computed tomography (HRCT) using a 
Multidetector Somatom Plus 4 CT-scanner (based on CT slices with 0.5 mm thickness). 
Whole animals were investigated with a native spiral scan (Fig. 3b).  
2.1 Pilot study 
In a pilot study on the optimum take rate, the parameters tumor cell number and sex were 
varied. For this purpose, male and female animals were observed for a period of 90 days 
after administering increasing tumor cell numbers. Two male and 2 female rats, 
respectively, received an injection into the superficial epigastric artery of the right hind leg 
containing 2.5x104, 7.5x104, 2.5x105 and 7.5x105 MDA-MB-231 or MDA-MB-231GFP+ cells.  
 
    
         a1)               b1) 
 
Fig. 3. (Continued) 
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         a2)               b2) 
 
    
         a3)               b3) 
 
Fig. 3. (a, b) Comparison of the lytic lesions of an untreated control rat detected by 2 
radiographic imaging techniques (lesions are indicated by arrows). 
(a) X-ray in a.p. position  a1) at day 30 after tumor cell inoculation, 
 a2) at day 66 after tumor cell inoculation, 
 a3) at day 104 after tumor cell inoculation. 
(b) Computed tomography scan reconstruction  
 b1) at day 30 after tumor cell inoculation, 
 b2) at day 66 after tumor cell inoculation, 
 b3) at day 104 after tumor cell inoculation. 
As a result, 50% of all animals developed discernible lytic lesions within an observation 
period of 90 days. In 5 of 8 males and in 3 of 8 females, overt lytic lesions were observed by 
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X-rays. The tumor take rate did not differ between MDA-MB-231 and MDA-MB-231GFP+ 
cells (4 of 8 animals, respectively). Cell numbers between 7.5x104 and 2.5x105 were found 
appropriate, as these animals developed more and bigger lesions in comparison to rats 
receiving higher or lower numbers of cells. In an additional group of 7 female nude rats, 
only 3 developed discernible lytic lesions after inoculation of 1x105 MDA-MB-231GFP+ cells. 
Overt lytic lesions were detected by X-rays in some animals as early as 3 weeks after tumor 
cell implantation. The inoculation of 1x105 MDA-MB-231GFP+ cells was well tolerated as 
animals recovered quickly from general anesthesia and did not show weight loss or any 
signs of walking with a limb.  
As a consequence, 1x105 MDA-MB-231GFP+ cells were inoculated into male rats as basis for 
all further animal studies. 
2.2 Evaluation of the animal metastasis model 
By using an amount of 1x105 tumor cells the corresponding tumor take rate was 92.7%. In 
the subgroup of control rats, 2 of 27 (7.4%) showed a spontaneous complete remission of an 
established lytic lesion within the observation period and 1 rat showed a delayed 
appearance of its lytic lesion at day 50 after tumor cell inoculation. 
The appearance of lesions was usually first detected in the distal femur and the proximal 
tibia of the hind leg inoculated with tumor cells. Thereafter, small single lytic lesions started 
to increase in extend and to become confluent with adjacent lesions. Advanced lytic tumor 
growth was associated with development of surrounding soft tissue metastasis in 8 of 25 
rats (32%), and with circular defects of cortical bone in 9 of 25 rats (36%). On average, soft 
tissue metastasis was detected earlier than circular cortical defects (60 days vs. 80 days after 
tumor cell inoculation, respectively), and was observed mainly in animals with fast growing 
lesions of the skeleton. In this rat model, the development of osteolytic lesions can be 
monitored up to at least 110 days after tumor cell inoculation. 
3. In vitro experiments for characterization of an IgY antibody 
The polyclonal antibodies used were developed in chicken against human bone sialoprotein 
II and were obtained from the company Immundiagnostik (Bensheim, Germany). 
Appropriate dilutions were made using PBS without Ca2+ and Mg2+. 
In this part of the study, MDA-MB-231GFP+ human breast cancer cells were exposed to an IgY 
antibody against bone sialoprotein II in order to determine the effect on proliferation, colony 
formation and migration (Table 1).  
Proliferation assay. A volume of 100 µl RPMI medium per well containing 5x103 MDA-MB-
231GFP+ cells was plated onto 96-well plates. After 24h 100 µl medium was added containing 
the anti-BSPII IgY antibody at final concentrations of 1-400 µg/ml anti-BSPII antibody. The 
plates were kept under standard cell culture conditions for 1-7 days of incubation. 
Thereafter, 10 µl/well of 3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyltetrazolium bromide 
(MTT; 10 mg/ml) was added to determine the number of surviving cells. The supernatant 
was removed after 3h of incubation, and formazan crystals that had been developed were 
dissolved by adding of 100 µl acidified 2-propanol/well (0.04 N HCl). Extinction was 
measured by an automated microtiter plate reader at 540 nm, reference filter 690 nm.  
It was found that a concentration below 1 mg/ml medium was ineffective. Higher 
concentrations gradually decreased cell proliferation with the highest concentration (400 
mg/ml) precluding any proliferative activity of MDA-MB-231GFP+ cells. The IC50 
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corresponded to 140 mg/ml at 7 days after start of treatment. Incubation of MDA-MB-
231GFP+ cells for up to 7 days with concentrations from 1 to 400 Ǎg/ml anti-BSPII antibody 
decreased the proliferation in a dose- and time-dependent manner as examined by MTT 
assay. The T/C% value of exposed cells decreased gradually from 101 (1 Ǎg/ml) to 5 (400 
Ǎg/ml) after 7 days of incubation (Table 1). 
Colony formation assay. For determining the response of MDA-MB-231GFP+ cells after 
exposure to the anti-BSPII IgY, 5x105 cells were pre-incubated for 48h in 2 ml RPMI medium 
containing anti-BSPII at concentrations of 1-400 µg/ml. Thereafter, MDA-MB-231GFP+ cells 
were harvested, counted and transferred into semi-solid medium with 0.8% RPMI-
methylcellulose and 30% FBS. Finally, 1 ml of the semi-solid medium containing 5x103 
MDA-MB-231GFP+ cells was plated onto 3.5 cm Petri-dishes. Triplicate Petri-dishes per 
treatment protocol were cultivated for 5-7 days at standard cell culture conditions. Colony 
formation (clusters of ≥30 cells) was visualized by staining with MTT and scored by an 
inverted microscope. 
The same range of concentrations as in the MTT assay was chosen to study the colony 
formation of MDA-MB-231GFP+ cells after exposure to the anti-BSPII immunoglobulin. 
Following 2 days of pre-incubation in medium, colony formation on methyl cellulose was 
dose-dependently inhibited, with T/C% values ranging from 107 (1 Ǎg/ml) to 17 (400 
Ǎg/ml; see Table 1). 
Migration assay. In a model for cell migration, 1x103 MDA-MB-231GFP+ cells were incubated 
with final anti-BSPII IgY concentrations ranging from 1 to 200 µg/ml. They had been 
incubated for 48h before being transferred into a transwell migration system. The breast 
cancer cells were plated on a polycarbonate filter membrane with a pore size of 8 µm (upper 
layer). The bottom layer was set up by 0.5 ml RPMI medium containing 1x104 SaOs-2 cells 
(osteosarcoma), which were grown in 24-well plates. After 24h the medium was removed and 
a semi-liquid RPMI medium containing 0.2% methylcellulose and 20% FBS was transferred 
on top of the SaOs-2 cells (0.5 ml/well) in order to maintain a gradient between the two 
compartments and to provide an additional barrier for cell migration. The polycarbonate 
filter was removed from the bottom layer after 24h of co-cultivation and transferred onto a 
fresh well containing bottom layer (see above). Cells migrating through the pores were 
counted daily for 4 days by fluorescence microscopy. The mean growth rate (MGR) of cells 
after migration through the polycarbonate filter was determined by the equation: 
MGR = log2 Nt - log2 N0/t, 
with N0 as initial cell number, Nt as final cell number and t as time period of cell incubation 
in days. 
Following pre-incubation for 2 days, MDA-MB-231GFP+ cells showed enhanced migration in 
response to 1 Ǎg/ml anti-BSPII (146 T/C%, day 1). Cells pre-incubated with higher 
concentrations of anti-BSPII (25-200 Ǎg/ml) showed decreased T/C% values ranging from 
92 to 11 (25-200 Ǎg/ml, day 1). This inhibition of migration decreased gradually with time. 
At day 4 after exposure, only cells pre-incubated with 200 Ǎg/ml anti-BSPII showed 
significantly reduced migration (59 T/C %) compared to untreated control cells. Cells that 
had migrated towards the bottom layer were allowed to proliferate for up to three days. 
Their mean growth rates (MGR; Table 1) ranged from 0.64 (25 Ǎg/ml) to 0.25 (200 Ǎg/ml), as 
compared to the MGR of untreated controls (0.80). A control IgY antibody did not show any 
significant effect (data not shown). 
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Assay  1 Ǎg/ml 25 Ǎg/ml 50 Ǎg/ml 100 Ǎg/ml 200 Ǎg/ml 400 Ǎg/ml 
Proliferation 
assaya 
100.9 86.9 77.1 62.7 26.9 5.3 
Colony 
formation assayb
106.6 94.2 86.4 54.2 43.2 17.3 
Migration assayc 
(MGR)d 
145.5  
(0.72) 
91.5  
(0.64) 
86.6  
(0.69) 
31.03  
(0.32) 
10.7  
(0.25) 
--- 
a Determined by MTT assay; T/C% values after 7 days of incubation with anti-BSPII IgY.  
b T/C% values of colony counts at day 7 after plating; for treatment the cells were pre-incubated with 
anti-BSPII IgY for 2 days. 
c Number of migrating cells in % of untreated control; T/C% values at day 1 after pre-incubation of 
MDA-MB-231GFP+ cells with anti-BSPII IgY. 
d Mean growth rate (per day): mean of growth rates (day 1/day 2 and day 2/day 3) determined in cells 
migrating through pores with a diameter of 8 Ǎm; MGR of control: 0.80. 
Table 1. Overview of in vitro results. 
4. Treatment of lytic skeletal metastasis with an anti-BSPII immunoglobulin 
The whole in vivo study comprised seven groups of nude rats with a total number of 81 
animals (Table 2). Untreated control rats (group 1) were observed for a period of 90 days. 
The effect of the antibody was assessed by either exposing MDA-MB-231GFP+ cells prior to 
their implantation (groups 2 and 3) or by treating rats bearing MDA-MB-231GFP+ cells early 
(group 4) or late (groups 5-7) after tumor inoculation (Fig. 4). Early treatment started at the 
day of tumor inoculation and additional s.c. injections were given 2 and 4 days later. Late 
treatment was administered to rats after the appearance of lytic lesions (Fig. 4). Treatment 
with erucylphospho-NNN-trimethylpropanolamine (ErPC3), used as control, was given i.v. 
after the onset of lytic lesions (31-34 days following tumor inoculation; group 5, Table 2) for 
a period of 8 weeks. Treatment with anti-BSPII IgY and the combination consisting of the 
alkylphosphocholine ErPC3 and anti-BSPII IgY was maintained over the same time period 
(groups 6 and 7, Table 2). The antibody and ErPC3 were tolerated well without any side 
effects. 
 
Group 
no. 
Animal no. 
(% total study) 
Mode of 
treatment 
Agent 
Concentration/
dosage 
Time period of 
exposure/treatment 
schedule 
1 25 (30.9)a 
Untreated 
control rats 
--- --- --- 
2 9 (11.1) 
Pre-treatment 
of cells (HDb) 
Anti-BSPII IgY 600 µg/ml 2hf 
3 11 (13.6) 
Pre-treatment 
of cells (LDc) 
Anti-BSPII IgY 25 - 100 µg/ml 48hf 
4 12 (14.8) Early treatment Anti-BSPII IgY 20 mg/kg s.c. Day 0, 2, 4g 
5 8 (9.9) 
Late treatment 
(APCd) 
ErPC3 60 µmol/kg i.v. 
Twice weekly for 8 
weeksh 
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Group 
no. 
Animal no. 
(% total study) 
Mode of 
treatment 
Agent 
Concentration/
dosage 
Time period of 
exposure/treatment 
schedule 
6 8 (9.9) 
Late treatment 
(ABe) 
Anti-BSPII IgY 10 mg/kg s.c. 
Once weekly for 8 
weeksh 
7 8 (9.9) 
Late treatment 
(APC + AB) 
ErPC3 + 
Anti-BSPII IgY 
60 Ǎmol/kg i.v. 
ErPC3 + 10 
mg/kg s.c. anti-
BSPII
Twice weekly 
(ErPC3) + once 
weekly (anti-BSPII) 
for 8 weeksh 
a Two rats with spontaneous regression were excluded; the initial number was 27.  
b High dose. c Low dose. d Alkylphosphocholine. e Antibody.  
f Pre-incubation of MDA-MB-231GFP+ cells before tumor implantation.  
g Three injections of 20 mg/kg were given subcutaneously on days 0, 2 and 4 after tumor 
implantation. h Treatment of rats after the occurrence of lytic lesions. 
Table 2. Design of in vivo experiments. 
 
 
Fig. 4. Time axis of in vivo experiment.  
In vivo experiments were performed with pre-treated MDA-MB-231GFP+ cells, which were 
incubated with anti-BSPII IgY for 2 days (group 3) or 2 h (group 2) before implantation into 
nude rats (pre-treatment). Animals of group 4 received the anti-BSPII IgY at the day of 
tumor implantation, as well as 2 and 4 days later (early treatment). In groups 5-7, treatment 
was administered to rats with lytic lesions for 8 weeks (late treatment). 
4.1 Pre-treatment 
The mean lytic lesion size of animals implanted with pre-treated MDA-MB-231GFP+ cells 
increased more slowly and was significantly smaller at days 70-90 than the corresponding 
mean lesion size of untreated controls (Fig. 5a). One of 11 rats (9%) did not develop any 
visible metastasis during the observation time of 90 days. 
Rats receiving pre-treated cells (groups 2 and 3) showed no circular defects of cortical bone 
or any soft tissue metastasis surrounding the lytic lesions during the observation time of up 
to 90 days (Table 3). Untreated control rats developed a circular defect of cortical bone in 9 
of 25 rats (36%) and soft tissue metastasis in 8 of 25 cases (32%; Table 3). In comparison to 
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untreated control rats, the average daily growth rate was distinctly lower in animals 
receiving pre-treated cells. For animals of group 2, the average daily growth rate was 0.07 
mm2 and for those of group 3 it was negative (-0.01 mm2). In contrast, lesions of untreated 
control rats increased by 0.55 mm2 per day on average. 
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Fig. 5a. Results of in vivo experiments. Comparison of the mean lytic lesion sizes of 
untreated control rats and animals receiving pre-treatment for 48 h (group 3). 
4.2 Late treatment 
The mean lesion size of animals receiving ErPC3 (group 5, Table 2) increased from day 30 (24 
mm2) to day 60 (63 mm2) after tumor implantation, and then reached a plateau (Fig. 5b). 
There was no statistically significant difference to untreated control rats during the 
observation time. The mean lytic lesion size of animals treated with 10 mg/kg anti-BSPII 
increased from day 30 (10 mm2) to day 60 (39 mm2) after tumor implantation (group 6, Table 
2; Fig. 5c). Thereafter, the average lesion size decreased significantly to a minimum size at 
day 90 (29 mm2, p<0.05) in comparison to untreated controls. The average daily growth rate 
was 0.32 mm2 compared to 0.55 mm2 for the controls (Table 3).  
The average lytic lesion size of animals receiving both, ErPC3 and anti-BSPII IgY (group 7, Fig. 
5c) increased minimally from 28 mm2 to 32 mm2 at day 60 and to 34 mm2 at day 90 after tumor 
cell implantation. The average growth per day was 0.1 mm2 (Table 3). At days 70 and 80, the 
mean lytic lesion size was significantly smaller than that of untreated control animals (30 mm2 
and 26 mm2, p<0.05). Animals receiving late treatment with the antibody alone or in 
combination showed fewer complications such as circular bone lysis or soft tissue metastasis 
caused by the growth of lytic lesions in comparison to untreated control rats (Table 3). 
The suitability of the anti-BSPII antibody for a combination therapy was tested by co-
administering the antibody with the alkylphosphocholine ErPC3. This agent has been shown 
to reduce proliferation, colony formation and migration in MDA-MB-231GFP+ cells in vitro. In 
nude rats with bone metastasis, this drug alone caused no reduction in lytic lesion size,  
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Fig. 5b. Results of in vivo experiments: Comparison of the mean lytic lesion sizes of 
untreated control rats and animals receiving late treatment with ErPC3 (group 5). 
but the combination with anti-BSPII IgY resulted in a significant decrease in mean osteolytic 
lesion size. Also, new bone formation was observed in rats treated with anti-BSPII IgY + 
ErPC3. This de novo bone formation resulted in almost complete remissions of lytic lesions as 
well as in stabilization of pathologically fractured bones in some rats (Fig. 6, Line VII c, d). 
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Fig. 5c. Results of in vivo experiments. Comparison of the mean lytic lesion sizes of 
untreated control rats and animals receiving the anti-BSPII IgY alone (group 6) or in 
combination with ErPC3 (group 7). 
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Parameter observed Group 1 Group 2 Group 3 Group 4 Group 5 Group 6 Group 7 
T/C% a (day 30) 100 37,.6b 67.2b 48.6b 143.1 56.1 164.1 
T/C% a (day 60) 100 18.7b,f 45.7b 29.9b,f 138.7 86.1 70.3 
T/C% a (day 90) 100 c 28.8b.f c 118.6 69.6 52.5 f 
T/C% a (day 90) 100 c 22.4b,f c 121.2 57.3 f 67.5 
Rats with circular defects of cortical 
bone (%)d 
9 (36) 0 (0)f 0 (0) f 0 (0)f 3 (37.5) 2 (25) 2 (25) 
Rats with soft tissue metastasis (%) 8 (32) 0 (0)f 0 (0) f 0 (0) f 3 (37.5) 2 (25) 1 (12.5) 
No. of rats without visible metastasis 
(%)/ 
--- 1 (11.1) 1 (9.1) 2 (20) --- --- --- 
No. of complete remissions (%)  2 (7.4) --- --- --- 2 (25) 1 (12.5) 0 (0) 
Average daily growth rate of lytic 
lesionse (day 30-90) (mm2) 
0.55 0.07 f -0.01 f 0.18f 0.61 0.32 f 0.10 f 
a Mean lytic lesion size of experimental rats in percent of the corresponding lesion size of untreated 
controls. b Mean value excluding rats without any visible metastasis.  
c Group terminated at day 60 after tumor implantation.  
d Circular defects of femur or tibia potentially resulting in a bone fracture; circular defects of the fibula 
were excluded.  
e Average daily growth rate from day 30 to 90 after tumor implantation for groups 1, 3, 5-7 and from 
day 30 to 60 for groups 2 and 4. f Significant difference versus control rats (p<0.05). 
Table 3. Results of in vivo experiments. 
Consequently, reduced osteolytic lesion sizes were observed in rats that had been treated 
with the antibody against BSPII before or after the appearance of skeletal metastasis. Beyond 
that, in rats with overt lytic lesions, at days 60 - 65 new bone formation was observed in the 
femur and tibia. On computed tomography reconstructions (Fig. 6) of this animal, the new 
bone formation in response to anti-BSPII treatment can be seen with greater plasticity. 
Remarkably, formation of new bone has previously not been described after treating overt 
osteolytic lesions. Even bisphosphonates being the most widely used treatment for patients 
with breast cancer bone metastasis are only able to delay the growth and progression of 
skeletal lesions by inhibiting osteoclast-mediated bone resorption. 
 
         A   B           C     D 
 
Fig. 6. (Continued) 
I 
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Fig. 6. Radiographic comparison of lytic lesions in the right hind leg of nude rats (lesions are 
indicated by arrows). Serial X-rays of experimental rats taken after 30-35 days (A), 40-45 
days (B), 60-65 days (C) and 80-95 days (D) after tumor cell implantation. 
Roman numbers denote individual animals, they correspond also to their group numbers 
and these rats are typical for the whole group. These include an untreated control rat (I, 
group 1), a rat (V) treated with ErPC3 (group 5), a rat (VI) treated with anti-BSPII IgY 
antibody, and a rat (VII) treated with ErPC3 plus the IgY antibody (group7). 
5. Combination treatment of lytic skeletal metastasis with the 
bisphosphonate zoledronate and the anti-BSPII IgY 
Over the last decades, bisphosphonates have become an essential part of the treatment of 
bone metastasis. They bind with high affinity to hydroxyapatite crystals and therefore 
accumulate in the skeleton. There they are potent inhibitors of osteoclast bone resorption 
and thus prevent or reduce the development of osteolytic lesions caused by breast cancer 
cells (28). Besides this established efficacy, N-containing bisphosphonates have been shown 
to inhibit the activity of farnesyl diphosphonate synthase, a key enzyme in the mevalonate 
pathway (29). In addition, these third generation bisphosphonates have been shown to exert 
cytostatic and pro-apoptotic effects on breast cancer cells in vitro (30). Nevertheless, 
treatment with bisphosphonates is considered as a palliative measure and therefore various 
drug combinations have been examined to improve the overall anti-neoplastic effect in 
breast cancer patients with skeletal metastasis (31-33). Among various options that can be 
envisaged the combination with an agent targeting the pathophysiology of skeletal lesions 
seems therapeutically attractive.  
V 
VII 
VI 
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In addition to these studies demonstrating that an IgY-antibody against BSPII was effective 
in reducing proliferation, colony formation and migration of MDA-MB-231GFP+ cells in vitro 
as well as in vivo it could be shown that this treatment induced new bone formation in the 
aforementioned nude rat model (34, 35). 
Therefore it was the aim of this study to combine a potent bisphosphonate, e.g., zoledronic 
acid, with the IgY antibody for treating the mammary carcinoma cell line MDA-MB 231GFP+, 
which causes osteolytic lesions in vivo. The combination of agents with unrelated 
mechanisms of action was expected to result at least in an additive combination effect.  
In order to explore a possible synergistic effect in lytic skeletal metastasis caused by MDA-
MB-231GFP+ cells, the rats were treated with combined exposure to zoledronic acid and the 
IgY antibody against bone sialoprotein II alone or in simultaneous combination. 
The experimental design is shown in Table 4. An untreated control group (group 1) was 
compared with five different treatment groups. The untreated control group was monitored 
radiographically over a period of 100 days after tumor cell inoculation. A possible 
preventive effect of zoledronic acid was tested on a group of ten rats (group 2) by 
administering 60 µg/kg (150 nmol/kg) subcutaneously on days 14 and 7 prior to tumor cell 
inoculation. This group was examined over a period of 70 days following tumor cell 
inoculation. Furthermore, zoledronic acid alone was used in an early treatment scheme prior 
to the development of lytic lesions (group III; n = 10; 60 µg/kg/week [150 nmol/kg/week] 
zoledronic acid, s.c.; d7-d28 after tumor cell injection) as well as in combination with the 
anti-BSPII IgY (group IV; n = 10; 60 µg/kg/week (150 nmol/kg/week) zoledronic acid, s.c.; 
d7-d28 after tumor cell injection plus 20 mg/kg anti-BSPII IgY, s.c.; d1, d3, d5 after tumor 
cell injection). These groups were also examined over a period of 70 days. 
In addition, two groups of rats (n = 10 each) with established lesions were treated according 
to a late treatment scheme. One of these groups (group V) received a late single drug 
treatment (60 µg/kg/week [150 nmol/kg/week] zoledronic acid, s.c.; d35–d84 after tumor 
cell inoculation) and the other group (group VI) was treated with a late combination 
treatment (60 µg/kg/week [150 nmol/kg/week] zoledronic acid, s.c.; d35–d84 after tumor 
cell inoculation and 10 mg/kg/week anti-BSPII IgY, s.c.).  
 
Group 
no. 
Animal no.
(% total study)
Mode of 
treatment
Agent 
Concentration/
dosage
Time period of exposure/ 
treatment schedule 
1 20 (28.57) 
Untreated control 
rats
--- --- --- 
2 10 (14.28) 
Pre-treatment of 
rats
zoledronic 
acid
60 µg/kg/week 
s.c.
Day 14, 7 before cell inoc. 
3 10 (14.28) 
Early single 
treatment
zoledronic 
acid
60 µg/kg/week 
s.c.
Day 7, 14, 21, 28 after cell 
inoc. 
4 10 (14.28) 
Early 
combination 
treatment
zoledronic 
acid + Anti-
BSPII IgY
60 µg/kg/week 
s.c. 20 mg/kg s.c.
Day 7, 14, 21, 28 after cell 
inoc. 
Day 1, 3, 5 after cell inoc.a 
5 10 (14.28) 
Late single 
treatment
zoledronic 
acid
60 µg/kg/week 
s.c.
Once weekly during 35d-
84db 
6 10 (14.28) 
Late combination 
treatment 
zoledronic 
acid + Anti-
BSPII IgY
60 µg/kg/week 
s.c. 10 mg/kg s.c.
Once weekly during 35d-84d 
following cell inoc. 
a before the appearance of lytic lesions. b after the appearance of lytic lesions. 
Table 4. Design of in vivo experiments. 
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5.1 Pre-treatment 
The mean lytic lesion size in animals receiving preventive treatment was significantly 
smaller than the mean lesion size of untreated controls at days 30–60. The increase in size of 
existing lesions was significantly lower (average daily growth rate: 0.3 mm2/d vs. 45.3 
mm2/d) as compared to untreated controls. The incidence of lesions was significantly 
reduced to 50%. Soft tissue metastases occurred in 20% (2/10) of rats which corresponds to 
half the incidence observed in untreated control rats (8/20; 40%). The significant reduction 
in lesion size was corroborated by analyzing the manifestation of lesions in the involved 
skeleton. Lesions in the femur and fibula were reduced by 55 and 65%, respectively, 
whereas lesions of the tibia were present in each animal affected. Also, the number of rats 
with periosteal defects of the cortical bone was significantly smaller as shown by a 60% 
incidence in the treated group versus 95% in the control group (Table 5). 
5.2 Early treatment 
The mean lesion areas of the early single drug and combination treatment schedules were 
almost identical. The initial mean lytic lesion areas were significantly smaller than the 
respective control area (4.0 and 4.8 mm2 vs. 25.6 mm2). Remarkably, the respective T/C% 
values of 15.5 and 18.6 at day 30 decreased with time to 5.5 and 6.5 at day 60. The average 
daily growth rate (mm2/d) was significantly reduced from 45.3 mm2/d in controls to 0.2 
mm2/d in animals receiving single drug treatment and to 0.1 mm2/d in those receiving the 
combination treatment. The incidence of lytic lesions was significantly reduced to 30% with 
both early treatment schemes corresponding to a 70% reduced incidence as compared with 
the control group. Periosteal defects of cortical bone were prevented totally with the early 
combination treatment and were reduced to 33% with the early single drug treatment. The 
appearance of lytic lesions was decreased by both early treatment schemes in the femur and 
fibula, the latter being significant (P ≤ 0.05). Soft tissue metastasis was not observed 
following the single drug treatment whereas the combination treatment was associated with 
a reduced incidence of 20% compared to 40% in the control group (Table 5). 
5.3 Late treatment 
With both late treatment schemes the mean lesion areas were significantly reduced as 
measured at 60 and 90 days following tumor cell inoculation. The late combination 
treatment improved the effect of zoledronic acid. For example, the mean lesion area at day 
60 following tumor cell inoculation was 93.5 mm2 in the control group, 31.3 mm2 in the late 
single drug treatment group and 19.5 mm2 in the late combination treatment group. The 
average daily growth rate of lytic lesions significantly decreased from 45.3 mm2/d (control 
group) to 0.3 mm2/d (late single drug treatment group), and to 0.2 mm2/d (late combination 
treatment group) after 60 days following tumor cell inoculation and from 22.7 mm2/d 
(controls) to less than 0.01 mm2/d (single drug treatment) and 0.05 mm2/d (combination 
treatment) after 90 days following tumor cell inoculation. The remission rate of lytic lesions 
was significantly increased to 40% (single drug treatment) and 30% (combination treatment) 
compared to the control group (5%, P = 0.015 and P = 0.057, respectively). The appearance of 
lytic lesions was reduced in all affected bones (femur, tibia and fibula) with both late 
treatment schemes. For lesions of the femur and fibula the combination treatment was 
slightly more effective than zoledronic acid alone, reaching almost significance (P = 0.06) for 
lesions of the femur. Similarly, the development of periosteal defects of cortical bone was 
significantly reduced in all three bones (P < 0.05) except for the femur following treatment 
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with zoledronic acid. Here, the late single drug treatment caused a reduction by 35% 
whereas the late combination treatment reduced this parameter by even 55%. In both late 
treatment groups just half as many rats developed soft tissue metastasis as compared to the 
control group (Table 5). 
The clinical dose of zoledronic acid in oncology is 4 mg i.v. every 3 – 4 weeks, which 
corresponds to about 110 µg/kg. Thus, a single experimental dose corresponded to about 
60% of a single clinical dose. When considering total dosages, the preventive regimen with a 
total of 120 µg/kg administered in two weeks is within the clinical range given within 3 – 4 
weeks. The early and late treatment regimens summed up to 240 and 480 µg/kg within 4 
and 8 weeks, respectively. These doses are about two fold higher than the equivalent clinical 
doses (4 and 8 mg within 4 and 8 weeks, respectively). Of note, the experimental doses are 
even lower than the clinically used doses if they are compared on the basis of body surface 
area. In this case the rats received single doses of about 0.4 mg/m2 body surface area as 
compared to 2.2 mg/m2 in patients. The corresponding total doses in rats were 0.8 mg/m2 
(pre-treatment), 1.6 mg/m2 (early treatment) and 3.2 mg/m2 (late treatment). The latter 
value is to be compared to 4.4 mg/m2 in the clinical situation for a period of 8 weeks. Thus, 
overall the dosages used in rats were equivalent to those in patients although tumors 
usually grow faster in rats than in humans. Therefore the single doses were given more 
frequently in rats in order to produce relevant results. 
The antiosteolytic effect of zoledronic acid in nude rats was only marginally increased by 
the IgY antibody. The therapeutic advantage was best discernible in the incidence of femoral 
osteolytic lesions when comparing zoledronic acid alone (80%) with the combination 
treatment (40%), but was less pronounced when comparing periosteal defects of cortical 
bone (60% vs. 40%). The main difference to the in vitro design was a lower dose of 
zoledronic acid in vivo (60 µg/kg) which already caused a maximum therapeutic effect and 
thus this effect could not be improved significantly by addition of the IgY antibody. A 
reason for this observation could be the pharmacokinetic property of bisphosphonates to 
accumulate in bone. The affinity of bisphosphonates for bone has been correlated with a 
long half-life and is similar to that observed for tetracyclines, strontium or fluoride. Thus, 
the skeletal concentration of zoledronic acid, together with its potency, was presumably too 
high to allow survival of the majority of osteoclasts and therefore caused the maximum 
antiosteolytic effect possible. In this scenario the IgY antibody could only show additional 
activity if it exerted a direct tumoricidal action or a stimulatory effect on osteoblasts. Both 
properties have been demonstrated in previous studies. Since zoledronic acid has 
tumoricidal properties as well, a clear difference between zoledronic acid and the 
combination would be hard to identify. Therefore, we hypothesized that a direct effect on 
osteoblasts may be the basis for the differences favoring the combination that were seen in 
response to the late treatment groups.  
It is unclear why the combination effect could best be observed in the femur of the animals. 
Recently, it has been described that osteolytic lesions induced by human MDA-MB-435 
breast cancer cells in nude mice were associated with a greater than 90% reduction in the 
number of osteoblasts. Based on this observation we speculate that the size of osteolytic 
lesions might be indicative for the extent of this effect, in that smaller lesions might be 
associated with a lower reduction in osteoblast counts as opposed to larger lesions. In that 
case those bones with initially smaller or less frequent osteolytic lesions such as the femur 
could be left with a higher number of osteoblasts which would be able to recalcify osteolytic 
lesions upon appropriate stimulation. 
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a Days following tumor cell inoculation. b Average daily growth rate.  
c Percentage based on all animals that were observed only or treated after the occurrence of lytic skeletal 
lesions. d Remission = Decrease in size ≥ 50% of initial size. *Significant effect versus control (P ≤ 0.05). 
Table 5. Effect of administering zoledronic acid alone and in combination with anti-IgY 
BSPII treatment. 
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In conclusion, the combination of zoledronic acid and the anti-BSPII antibody caused only a 
low therapeutic advantage over zoledronic acid alone, probably due to a maximum anti 
osteolytic effect caused by the bisphosphonate alone. Nevertheless, an almost significant 
effect was observed in parameters indicating recalcification such as the reduction of 
osteolytic lesions and the prevention of periosteal defects of cortical bone. These 
observations may favor using the IgY-antibody in addition to zoledronic acid in order to 
stimulate osteoblast induced recalcification. 
6. Treatment of lytic skeletal metastasis with antisense oligonucleotides 
against OPN and BSPII 
Here, we report on the selection of antisense oligonucleotides (ASOs), which are effective in 
reducing their protein levels. We considered the two proteins to be potential targets for 
treatment in order to slow down or suppress the formation of bone metastasis. For a specific 
treatment, we identified antisense oligonucleotides that are capable of reducing the 
expression levels of OPN and BSPII. The activity of these ASOs was determined by Western 
blot and by inhibition of colony formation as well as of metastasis formation of pre-exposed 
MDA-MB-231GFP+ human mammary carcinoma cells (36, 37). 
Selection of ASOs 
The suitability of 10 different ASOs per gene was predicted by using the HUSAR program 
‘‘Mfold’’, which takes RNA folding into account. Application of this program onto the cDNA 
sequence of OPN (acc. no. gi:3360431) and BSPII (acc. no. gi:11435526) resulted in the 
recognition of RNA stretches that probably contain bulges or loops, that are preferentially 
single stranded and thus allow access of DNA antisense structures. ASOs of 20 base pair 
length were selected against these single-stranded regions and synthesized with a 
phosphorothioate backbone, to increase stability against degrading enzymes (Table 6). 
Controls included a nonsense oligonucleotide (NSO) derived from the HBV genome that 
served as a control for unspecific effects of a 20 bp long phosphorothioate oligomer. In 
addition, its base composition differed only slightly from the mean composition of all ASOs 
used (A:3 versus 4.1; C:4 versus 4.4; G:6 versus 4.8; T:7 versus 6.6). Sequence-specific effects 
were controlled by using ASOs differing by three base pairs with regard to the respective 
cDNA sequence. Finally, the use of 10 ASOs per target gene allowed to include sequences that 
were scrambled (identical in base composition) except for two bases that were permutated. 
For determining the potential secretion of OPN and BSPII, an MDA-MB-231GFP+ subline was 
generated, which was selected by continuously reducing the FBS content of the medium, 
until the cells kept growing without FBS. This cell line was denoted as MDA-MB-231F. All 
cells were kept in log-phase, and passaged 1 – 3 times per week depending of their growth 
rate, and maintained under standard conditions (37°C, humidified atmosphere, 5% CO2). 
Stock solutions of ASOs in distilled water were diluted to appropriate concentrations with 
phosphate-buffered saline (PBS). For transfecting cells with ASOs, lipofectamine (Lipofectin, 
Invitrogen, Karlsruhe, Germany) or electroporation was used. 
ErPC3 
For treating MDA-MB-231F cells, ErPC3, which was kept as stock solution in ethanol and 
PBS (10mM; ratio of diluents 1:1; V:V), was diluted in PBS resulting in final concentrations 
of 10, 14 and 20 mM. The medium containing ErPC3 was changed after 24 hours in all 
experiments and the cells were further grown for 48 – 72 hours without ErPC3 (for details of 
sequential exposure see below). 
www.intechopen.com
 Treatment of Breast Cancer Lytic Skeletal Metastasis Using a Model in Nude Rats 
 
471 
No. (OPN)a cDNA (BSPII)a cDNA 
ASO-01 
bp 73–92 bp 46–65
5'-CTC ATG GTA GTG AGT TTT CC-3' 5'-TGA TTG CTT CCT CTG GCA GT-3' 
ASO-02 
bp 661–680 bp 53–73
5'-TTC AGG TCC TGG GCA ACG GG-3' 5'-ATT TTG GTG ATT GCT TCC TC -3' 
ASO-03 
bp 662–681 bp 328–347
5'-GTT CAG GTC CTG GGC AAC GG-3' 5'-CTT CAT TGT TTT CTC CTT CA-3' 
ASO-04 
bp 1343–1362 bp 331–350
5'-CTA ACT TAA AAA ACA AAA GA-3' 5'-ATT CTT CAT TGT TTT CTC CT-3' 
ASO-05 
bp 1346–1365 bp 505–524
5'-ACA CTA ACT TAA AAA ACA AA -3' 5'-CTT CAT CAC TTT CCT TCT CT-3' 
ASO-06 
bp 193–212 bp 546–565
5'-GTG GCC ACA GCA TCT GGG TA -3' 5'-GCT TTC TTC GTT TTC ATT TC-3' 
ASO-07 
bp 193–212 bp 706–725
5'-GTG GCC ACA GCA TCT GGG TA-3' 5'-TTC CGG TCT CTG TGG TGT CT-3' 
ASO-08 
bp 195–214 bp 711–730
5'-ATG TGG CCA CAG CAT CTG GG-3' 5'-CTG CCT TCC GGT CTC TGT GG -3' 
ASO-09 
bp 556–575 bp 1003–1022
5'-GGT CTG CGA AAC TTC TTA GA-3' 5'-ACT GGT GGT GGT AGT AAT TC-3' 
ASO-10 
bp 559–578 bp 1005–1024
5'-TCA GGT CTG CGA AAC TTC TT-3' 5'-TCA CTG GTG GTG GTA GTA AT-3' 
The following sequence from HBV was used as a nonsense control (NSO): 5’-GCG AGG GAG TTC TTC 
TTC TA-3’. aThe combination of the abbreviation of the gene and the number of a given ASO was used 
for its naming. 
Table 6. Selected antisense oligonucleotides against OPN and BSPII. 
Electroporation 
Pending on the duration of treatment, 5x105 – 3x106 cells were suspended in 1ml RPMI 1640 
medium without phenol red containing 10 mM concentrations of the respective ASO or 
NSO. For transfection, the cells were pulsed two or three times for 2ms at 450 or 350V, 
respectively, in an 800 ml cuvette using an electroporation impulse generator (EPI2500, Dr L 
Fischer, Heidelberg, Germany) with the capacitance set at 1200 mF. Thereafter, the cells 
were plated onto six-well plates and grown for 48 – 72 hours. 
Lipofectamine 
Pending on the duration of treatment, 1x105 – 3x105 cells were transferred onto six-well 
plates and grown for 24 hours. For transfection, ASO stock solutions were prepared in 
medium without FBS. According to the protocol of the manufacturer, the respective ASO 
stock solution was mixed with lipofectamine to allow ASO–liposome complexes to form. To 
200 ml medium containing ASO quantities resulting in 10 mM (Western blot and in vivo 
model) and in 5, 10, or 20 mM (clonogenicity assay) final ASO concentrations, an equal 
volume of medium without FBS was added containing 5, 10 or 20 ml lipofectamine, 
respectively. In addition to the ASO treatment, an NSO control (20 mM final concentration 
with 20 ml lipofectamine) and a lipofectamine control (20 ml) were used. Based on the 
equilibrium of the ASO–liposome complex formation, the relatively low amount of 
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lipofectamine used resulted in effective ASO concentrations that were at least by a factor of 
10 lower than those in the medium used for transfection. After 12 hours the medium was 
changed, and cells were further grown for 48 – 72 hours. In the case of a sequential 
combination treatment this first cycle was repeated with the respective combination partner. 
Combination treatment 
Sequential combination treatment consisted of two or three treatment cycles. The two-cycle 
treatment started either with the ASO and was followed by ErPC3 or was performed with 
the reverse sequence. The three-cycle treatment started either with two cycles of ASO 
followed by ErPC3 or an initial exposure to ErPC3 was followed by two cycles with an ASO. 
Verification of the ASOs treatment by Western blotting 
Transfected cells were incubated, harvested and washed. Thereafter 2x106 cells were 
counted and prepared for Western blotting. The protein concentration of the lysate was 
determined using the BCA protein assay from Pierce (Rockford, IL) according to the 
manufacturer’s recommendation. After the cell lysates were separated by electrophoresis 
and transferred to a PVDF membrane, the membrane was incubated with the respective first 
antibody (OPN: rabbit–antihuman polyclonal or mouse–antihuman monoclonal antibody; 
BSPII chicken–antihuman or rabbit–antihuman polyclonal (all from Immundiagnostik, 
Bensheim, Germany)). An HRP-conjugated anti-mouse, anti-rabbit or anti-chicken 
secondary antibody (all from Immundiagnostik, Bensheim, Germany) and ECL (Amersham 
Biosciences, Freiburg, Germany) were used to detect the respective proteins by exposing the 
membrane to an X-ray film. To control for variations in loading, the membranes were 
stripped for 30 minutes at 56°C in stripping solution. Thereafter, they were reprobed with 
an antibody against β-actin (mouse monoclonal antibody, Santa Cruz.CA), and a secondary 
goat anti-mouse polyclonal antibody (Santa Cruz.CA). 
 
Target protein  OPN BSPII
Type of exposure Singlea Twofolda Singlea Singleb Singlea Twofolda 
ASO-01 25 34 45 78 58 16 
ASO-02 45 60 38 94 94 --- 
ASO-03 32 38 97 44 93 --- 
ASO-04 16 23 73 55 109 --- 
ASO-05 43 80 27 63 101 49 
ASO-06 45 68 33 16 79 19 
ASO-07 31 69 58 25 37 22 
ASO-08 48 97 62 34 101 25 
ASO-09 --- 74 35 46 84 --- 
ASO-10 --- 86 33 40 30 --- 
NSO 99.5 99 100 99 100 97 
Control 100 100 100 100 100 100 
a Transfection with lipofectamine. b Transfection with electroporation. 
The used cell line was MDA-MB 231F. X-ray films documenting chemoluminescence bands were scanned, 
digitized bands of the respective protein were expressed in relation to untreated control (100%). 
Table 7. Inhibition of OPN and BSPII expression in MDA-MB 231F cells following exposure 
to a series of antisense oligonucleotides. 
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The X-ray films were automatically processed and scanned by using an imaging program. 
The digitized bands of the respective proteins were given as percent of control and corrected 
for differences in loading by referring to the intensity of the β-actin band. The Western blot 
results of protein expression after exposing mammary carcinoma cells to ASOs directed 
against OPN and BSPII mRNA are shown in Table 7. Systematic comparisons showed that 
ASO-OPN-04 and ASO-BSPII-06 were the most effective structures within the respective 
series. Single exposure of cells was enough to reduce the OPN expression by 84% in 
response to ASO-OPN-04. This effect was not increased by repeating the ASO exposure, but 
the protein concentration was kept at a comparable level (77%). A similar efficacy was 
obtained for ASO-BSPII-06, which caused an 84% reduced bone sialoprotein II expression 
following single exposure and an 81% reduced protein level following two-fold exposure. 
In vivo model 
In order to induce loco regional bone metastasis, and to investigate a preventive effect of the 
ASOs, 1x105 MDA-MB 231F cells (control or pre-exposed to ASOs) were injected into a 
branch of the femoral artery of a nude rat, as described above. After an average of 28 days 
following the inoculation of control cells, lytic metastases could be detected by X-rays. The 
size of these lesions, which exclusively occurred in the femur, tibia and fibula of the animals, 
was recorded for up to 10 weeks. 
The results of the in vivo experiments are shown in Table 8. Exposure to the ASO-OPN-04 
and ASO-BSPII-06 for 3 days before implantation into nude rats caused a significantly 
reduced tumor take rate, as assessed by the appearance of osteolytic lesions following 
exposure to ASO-OPN-04, and a reduced size of osteolytic lesions in the X-ray-positive rats 
following both agents. 
 
Group 
no. 
Animal 
no.  
Agenta 
Observation 
period (weeks)
Incidence of 
metastasis
Size of 
lesionb
Mean T/Cx100c 
1 4 ASO-OPN-04
4 1/4 0, 0, 0, 34 8.5(717)d 3.9 
6 1/4 0, 0, 0, 46 11.5(723) 3.8 
8 1/4e 0, 0, 0, 60f 15(730) 4.3 
2 4 ASO-BSPII-06
4 1/4 0, 0, 0, 14 3.5(77) 1.6 
6 1/4 0, 0, 0, 35 8.8(718) 2.9 
8 2/4 0, 0, 20, 106f 31.5(751) 9.1 
3 2 NSO 
4 2/2 106, 240 173(134)g 78 
6 2/2 162, 411  287(249) 95 
8 2/2 242, 728 485(486) 140 
4 2 
Untreated 
cells control 
rats 
4 2/2 314, 127 221(187) 100 
6 2/2 386, 218  302(168) 100 
8 2/2 425, 266 346(159) 100 
a MDA-MB-231F cells were exposed to ASOs or NSO (transfected with lipofectamine), before 
transplantation to nude rats. b Product of pixel number and mean black intensity in individual rats as 
determined by image analysis from the X-ray radiograph. c Mean lesion size of treated over control rats 
times 100. d Numbers in brackets denote SD. e P = 0.0028 vs. control groups 3 and 4.  
f P = 0.05 vs. control groups 3 and 4. g Numbers in brackets denote range. 
Table 8. Results of in vivo experiments. 
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Nude rats that received 1x105 untreated or NSO-treated MDA-MB-231F breast cancer cells 
developed bone metastasis in four of four cases (Table 8). The metastatic lesions were 
detectable for the first time after 4 weeks and were nearly doubled in size until week eight. 
Three of four rats that received 1x105 MDA-MB-231F breast cancer cells pre-treated with the 
ASO, directed against OPN, developed no discernible metastasis within the observation 
period (P=0.028). One of the four rats developed lytic metastasis, but this lesion was 
distinctly smaller in size than those in control rats (week 4; P=0.05). Similarly, two of four 
rats that received 1x105 MDA-MB-231F breast cancer cells pre-treated with the ASO directed 
against BSPII remained free of visible metastasis within the observation period of 8 weeks; 
one rat showed lytic metastasis after 4 weeks already, another rat developed a metastasis 
after 8 weeks. Thus, exposure to both, ASO-OPN-04 and ASO-BSPII-06, was associated with 
a significantly reduced lesion size, and the former agent caused a significantly reduced 
incidence of lesions, as well. 
7. Biodistribution and efficacy of polymeric nanoparticles containing OPN 
and BSPII antisenses in a mammary carcinoma rat model 
The initial steps in metastasis include invasion of tumor cells into normal tissue, traversion of 
small blood vessel walls and thus access to the circulation (38). Cancer cells that survive these 
initial steps can enter the sinusoids of the bone marrow and migrate across the sinusoidal wall 
to the endosteal bone surface (39). For homing into the bone compartment, tumor cells have to 
develop specific functions that differ from those in the normal tissue and they presumably 
express several proteins that assist in this process (40). Osteopontin and bone sialoprotein II, 
have both been characterized as promising targets for a therapy by antisense oligonucleotides 
directed against the RNA of these proteins, thus preventing or reducing lytic skeletal 
metastasis (36, 37). Efficient and specific delivery of antisenses (ASOs) and a protection of the 
sequences from degradation are the crucial conditions for ASO therapeutic efficiency. Due to 
their large molecular size and high negative charge density, the resulting low cellular 
permeability of ASOs is a major problem encountered with their therapeutic use (41-43). To 
improve cellular delivery of ASOs several methods, employed in DNA delivery, have been 
developed including viral vectors, liposomes, and other delivery systems (44-46). 
Especially one of these nanocarrier systems, the nanoparticles (NP), has been increasingly 
employed as drug delivery devices of small molecules and particular nucleic acids (47). The 
nanocarriers are utilized to protect molecules from biodegradation as well as to modify their 
pharmacokinetics and biodistribution (48).  
It was hypothesized that effective and safe ASO delivery could be achieved by polymeric 
nanoparticles (NP) fabricated from the biocompatible and biodegradable PLGA. Poly(lactic-co-
glycolic acid) copolymers (PLGA) are among the few synthetic biocompatible biodegradable 
polymers approved for human gene therapy use (49). Due to their nano-size range and small 
negative charge, polymeric nanospheres containing ASOs can overcome the absorption barrier 
of the cell membrane by penetrating inside the cell via endocytosis (50, 51). Moreover, the 
controlled release delivery mode offers increased resistance to nuclease degradation, sustained 
duration of ASO administration, and consequently, prolonged antisense action. 
In this section we report about the characteristics and therapeutic efficiency of a controlled 
release nanoparticle (NP) delivery system for ASO sequences, designed against OPN and 
BSP II. The ASO-NP efficiency in the inhibition of metastatic bone lysis was evaluated in the 
rat animal model of mammary carcinoma (52, 53). 
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ASO NP preparation and characterization 
A double emulsion system and the solvent evaporation technique were used to incorporate 
OPN-ASO sequences in PLGA (53). At the end of production finished NP were lyophilized 
and the dry NP were stored in a vacuum desiccator at 4°C. The amount of ASO entrapped in 
the NP was analyzed and determined using the fluorescence “Oligreen assay kit” 
(Molecular Probes, Eugene, OR) and by UV spectroscopy at ǌ = 260 nm.  
NP size and morphology were evaluated by dynamic light scattering, ALV (NIBS/HPPS 
GmbH, Langen, Germany), and a transmission electron microscope (TEM CN12, Philips, 
Eindhoven, The Netherlands). Average size and size distribution of empty NP and NP 
loaded with ASO sequences were measured before and after lyophilization. A zeta-sizer 
(Malvern Instruments Ltd, UK) was used for evaluation of NP charge (Tab. 9).  
Several types of NP have been prepared for the various studies, empty NP (blank, serving as 
control), NP loaded with NS (control), NP containing OPN or BSPII ASO (ASO-NP); and 
fluorescent NP including, NP loaded with FITC-ASO (FITC-NP), fluorescent empty NP 
(PLGA-rhodamine, Rhodamine-NP), and double labeled NP (ASO-FITC and PLGA-
rhodamine). 
 
 Size distribution (nm) 
Surface charge 
(ζ potential, mV)
Loading 
NP 
content 
Before 
lyophilization 
After 
lyophilization 
Yield (%) 
Concentration 
(µg AS/mg polymer) 
OPNa 234 ± 72 281 ± 85 3.06 ± 0.84 51 ± 9 4.80 ± 0.68 
BSPIIb 236 ± 73 294 ± 98  3.88 ± 0.74 55 ± 14 4.56 ± 1.07 
NS  233 ± 70 280 ± 90  2.37 ± 0.47 49 ± 13 6.91 ± 2.82 
Empty 291 ± 85 324 ± 104  2.6 ± 0.06 --- --- 
Mean ± SD, each batch was measured in triplicate. aOPN = ASO-OPN-04 and bBSPII = ASO-BSPII-06 
(Tab. 6) 
Table 9. The physicochemical properties of AS NP examined. 
7.1 Biodistribution pilot study in healthy rats 
In a pilot study we tried to clarify the distribution of the nanoparticles in the organism (rat). 
Therefore the ASO-OPN-04 sequence (Tab. 6) was internally labeled with 33P (54). 
The used rats were randomly assigned to treatment or control groups. Naked ASO-OPN-04 
(n = 4) or ASO-OPN-04-NP (n = 5) were injected into a rat tail vein at average 13.2x106 
DPM/rat. Rats injected with saline were used as a control group (n = 2). The rats were kept 
in metabolic cages and their excrements were collected every day. The animals were 
euthanized 24 h, 72 h, and 7 days post-injection. One milliliter of blood, 0.5 ml of urine, 
whole organs, samples of skeletal muscles, and feces were taken from each rat for analysis. 
The radioactivity (DPM = disintegrations per minute) in the samples was counted by means 
of a liquid scintillation analyzer (Packard, Tri-carb 2900TR, USA) against a calibration curve 
of R2 = 0.986. The radioactivity was normalized to the animal weight and an organ 
accumulation was expressed as a percentage of total injected doses (Fig. 7a-c). 
Following the above experiment in certain tissues a quantitative examination of the whole 
body biodistribution was performed comparing naked and NP encapsulated ASO. 
Levels of naked ASO increased considerably in most tissues after 24 h, reaching highest 
values in the liver and spleen. Naked ASO was also found at higher levels in blood, in 
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comparison to NP encapsulated sequences (9.3 ± 1.0% and 7.7 ± 1.2% naked ASO vs. 3.2 ± 
0.5% and 1.9 ± 0.4% ASO-NP after 24 h and 72 h, respectively), but the naked ASO amount 
was insignificant (0.3 ± 0.0%) after 7 days, when ASO-NP level in blood started to increase 
(4.0 ± 0.9%). Throughout the time-course of the study, ASO-NP was distributed mainly in 
the liver and spleen. The total recovery from these two organs was as much as 46.4 ± 3.0% 
and 74.2 ± 7.4%, 24 h and 72 h after the treatment, respectively, and slightly decreased to 
59.3 ± 8.9% after 7 days. In contrast, naked ASO sequences accumulated in the spleen to a 
much lower extent (2.8% ± 0.4% after both 24 and 72 h, and 1.6% ± 0.1% after 7 days). 
Although relatively high amounts of naked ASOs reached the liver during the first half of 
the study (33.8% ± 1.7% and 26.7% ± 4.8%, after 24 and 72 h, respectively), only 8.1% ± 1.4% 
were found in this organ after 7 days (Figure 7c). Throughout the study naked ASOs 
accumulated to a small extent in the thymus (2.8% ± 0.9%, 3.8% ± 4.8%, and 1.8% ± 0.3% 
after 24 h, 72 h, and 7 days, respectively). Relatively low levels of ASO, both naked and NP  
 
 
 
Fig. 7. (Continued) 
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Fig. 7a-c. The quantitative biodistribution of ASO-NP in whole body organs. 
Naked (n = 4) or NP (n = 6) encapsulated sequences were internally labeled with 33P ATP 
and were injected into a healthy male rats (350–400 g) tail vein (average 13.2×106 DPM/rat). 
Rats injected with saline were used as the control group (n = 2). Biodistribution was 
evaluated 24 h (a), 72 h (b), and 7 days (c) after treatment by beta-counter analysis of blood, 
organs, and excrement samples. The radioactivity was normalized to the animal weight and 
organ accumulation was expressed as a percentage of total injected dose (mean ± SD). Bars: 
blue – ASO NPs, red – naked ASO. 
encapsulated, were found in the kidneys at all time points, but always the amount of naked 
ASO in the kidneys was higher than that of NP encapsulated sequences (1.7% ± 1.0%, 2.5% ± 
0.3%, and 1.4% ± 0.3% naked AS vs. 0.8% ± 0.1%, 0.5% ± 0.1%, and 1.2% ± 0.2%, ASO-NP 
after 24 h, 72 h, and 7 days, respectively). At all time points of the experiment, the 
accumulation of NP encapsulated ASO was negligible in other organs harvested. Mostly 
~1% or less of the injected dose was found in the skeletal muscles, lymph node, pancreas, 
adrenals, brain, spinal cord, heart, and lungs. Naked ASO was taken up by those tissues to a 
higher extent than ASO-NP. 
Naked ASO and ASO-NP had different clearance profiles. Throughout the study course 
naked ASO was excreted mainly and rapidly in urine, due to the highly hydrophilic 
nature of the ASO and its degradation products. Already after 7 days more than half of 
the naked ASO dose injected was cleared in the urine. In contrast, ASO-NP was excreted 
in the urine to a lower extent, and a significant amount was also found in the feces at all 
time points. After 7 days, the clearance of ASO-NP was mostly in feces, whereas only a 
small ASO amount was found in the urine. The divergent clearance suggests different 
degradation rate and extent of naked and encapsulated ASO. Following the treatment 
with naked ASO, all the sequences can be rapidly degraded and cleared in urine. In ASO-
NP formulation only the released ASO is exposed to degradation, but encapsulated ASOs 
remains intact and generally can be found in tissues or excreted in the feces. Moreover, 
most of the encapsulated ASO was released inside the cells, because of the rapid cellular 
uptake of NP; hence it is less exposed to degradation by nucleases existing in the 
extracellular matrix.  
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It can be concluded that ASO-NP protects the ASO from degradation and provides efficient 
ASO delivery to the tumor tissue. Moreover, administration by the NP delivery system 
minimizes ASO accumulation in intact organs due to the ASO sustained release profile, and 
the favorable NP physicochemical properties. 
7.2 NP effects on cells in vitro 
NP effect on cells’ viability 
HeLa cells (1.5 x 104/chamber) were seeded in a Lab-Tek chambered cover glass system and 
incubated for 24 hr. The cells were treated with empty NP (10 mg/ml) and were incubated 
for 24 or 48 hr. At each time point, the cells were washed with PBS and harvested. The total 
cells’ number and amount of living and dead cells were counted, using a hemocytometer. 
Trypan blue was used for staining dead cells. Non-treated cells were used as a control 
group. The percentage of living and dead cells was calculated. Statistical differences 
between NP treated and non-treated groups were tested at each time point by the one-tailed 
unpaired Student’s test. Differences were considered statistically significant at p < 0.05. 
The average cells’ number (living and dead) was similar in treated and non-treated groups 
24 hr after treatment (living cells, 95.0% and 96.3%; and dead cells, 5.0% and 5.2% in NP 
treated and non-treated groups, respectively), as well as after 48 hr (living cells, 94.8% and 
95.6%; dead cells, 5.2% and 4.4% in NP treated and untreated groups, respectively). 
In vitro visualization of cellular uptake 
The cellular uptake of fluorescent ASO sequences encapsulated in rhodamine-labeled 
PLGA-NP by HeLa and MDA-MB-231 tumor cells was examined. MDA-MB-231 and Hela 
cells (1.5 x 104/chamber) were seeded in a Lab-Tek chambered cover glass system (Nunc 
International Corp.) and incubated for 24 hr. Fluorescent NP loaded with FITC-ASO or 
naked FITC-ASO sequences were added to the cells and incubated for 4, 24 or 48 hr. 
After methanol fixation the cells were mounted with fluorescence microscopy mounting 
media. ASO-NP uptake in comparison to naked AS was observed and recorded by means of 
confocal microscopy (Zeiss LSM 410, Germany). Nontreated cells and cells incubated with 
empty NP were determined as background. Confocal cross-sections of cells taken at 24 and 
48 hr after treatment were used to verify intracellular (cytoplasmic) localization of the NP 
and the ASO. 
Empty fluorescent NP were shown to internalize and accumulate in the cytoplasm of both 
HeLa and MDA-MB-231 cancer cells, reaching maximal uptake within the first 24 hr (figure 
not shown). No significant auto-fluorescence was observed in HeLa cells chosen for further 
uptake evaluation experiments. Similarly to the empty NP, ASO loaded NP were 
internalized by the cells and accumulated in the cellular cytoplasm. High NP internalization 
was achieved by 24 hr. In contrast, naked ASO uptake was decreased overtime. Confocal 
cross-section images of HeLa cells 24 and 48 hr after treatment with ASO-NP verified cell 
internalization and cytoplasm localization of the NP. 
Cells treated with empty NP exhibited a relatively high uptake of 13.6 ± 0.01% already after 
4 hr, followed by a gradual increase and thus reaching maximum uptake after 24 hr (44.02 ± 
0.68%), and a slight decrease after 48 hr (39.65 ± 0.02%). Treatment with naked ASO resulted 
in a significant uptake (17.18 ± 0.83% of the cells) already 4 hr after treatment. The naked 
ASO internalization rate increased to its maximum level after 24 to 48 hr (35.22 ± 19.19% and 
30.40 ± 0.11%, respectively). In spite of a relatively rapid NP internalization, fluorescent 
www.intechopen.com
 Treatment of Breast Cancer Lytic Skeletal Metastasis Using a Model in Nude Rats 
 
479 
signal from FITC-ASO encapsulated in NP was detected in less than 10% of the cells after 8 
hr. In contrast, the number of cells loaded with ASO was markedly increased after 24 hr, 
reaching 58.81 ± 25.75%. 
Extent and intensity of NP endocytosis: The representative experiments demonstrate the 
continued uptake over time of ASO-NP. After 24 hr, a significant increase of NP uptake was 
exhibited in cells treated with empty rhodamine-NP. ASP-NP internalization (encapsulated 
FITC ASO) was also observed after 4 hr, but to a lesser extent than naked ASO. In contrast, 
the fluorescence of FITC-ASO in NP was markedly increased after 24 hr, and was much 
higher than that of naked ASO. Internalization of naked ASO was significant already after 4 
hr (41.48 ± 0.03). The AS accumulated inside the cells, reaching 63.22 ± 0.01 and 74.45 ± 0.11, 
after 24 and 48 hr, respectively. In contrast, empty NP uptake was slower, 21.12 ± 0.01 after 4 
hr, increasing gradually to 46.43 ± 0.01 after 24 hr. The uptake of rhodamine-NP was 
decreased after 48 hr. Following treatment with ASO encapsulated in non-fluorescent NP, 
relatively low levels of ASO were detected inside the cells after 4 and 8 hr, increasing 
significantly after 24 hr (150.25 ± 0.87). 
7.3 Bioactivity – Inhibition of metastatic bone lysis by OPN and BSPII ASOs 
The tumor cells were inoculated as described above (see chapter 2). Resulting bone 
metastases and their mean lytic lesion size was followed by X-ray examinations once weekly 
for 12 weeks. Treatment results were observed in groups of 4–5 rats at each arm of the 
studies. The lesion size was measured from X-ray pictures using image analysis software, 
and the mean lesion size and lesion ratio (mean lesion size in treated group in percent of 
control) were calculated. The mean lesion size was presented in relative units (RU), 
corresponding to the image analysis of the pixel’s count. 
The results were expressed as mean ± SD. Statistical differences between groups in the 
metastatic lesion size were assessed by the one way ANOVA test. 
The treatment with NP, loaded with ASOs (OPN or BSPII), was administered immediately 
after tumor inoculation into the same vessel as the cells (superficial epigastric artery, Fig. 2). 
The amount of NP (100 mg in 500 µl PBS, total dose of 600 µg of NSO or ASO) was divided: 
two thirds of the dose was injected into the vessel and one third (using the same needle) was 
injected loco regionally, into the muscle surrounding the knee joint (in order to avoid 
clogging of the artery). 
The inhibition of metastatic bone lysis by OPN and BSPII ASO-NP was evaluated in a rat 
mammary carcinoma metastasis model. Most animals treated with nonspecific NSO 
delivered by NP (4 of 5 rats) developed bone metastasis (Tab. 10) and multiple lesions in the 
femur, tibia and fibula. The metastatic lesions were detectable for the first time after 4 weeks 
(mean lesion size of the control group, 16 ± 14 RU, doubled in size until week 8 (38 ± 36) and 
continued to grow in all rats till the end of the experiment (week 12). 
Treatment with OPN ASO and BSPII ASO loaded NP resulted in a significant decrease in 
tumor bone metastasis incidence, as assessed by the reduced appearance of osteolytic 
lesions (Table 10) and in a reduced size of the lesions in metastasis-positive rats. Two of 
the 4 rats developed lytic metastasis following the treatment with OPN NP, and 3 of 5 
with BSPII NP, but the lesions in the ASO NP treatment groups were distinctly smaller in 
size than those in the control group of NSO-NP (Table 10). Both ASO sequences 
successfully prevented metastasis incidence and even caused tumor regression in most 
animals; 3 of 4 and 3 of 5 animals were found free of visible metastasis at the end of the 
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observation period (week 12) following the treatment with OPN and BSPII NP, 
respectively (Table 10). It was found that the BSPII ASO had a response by the inhibition 
of metastasis, but it was somewhat less effective than OPN ASO in bone lysis reduction, 
when delivered by NP. 
 
Treatment type 
Time 
(weeks) 
Metastasis incidence 
(tumor bearing rats / animals)  
Mean lesion size1
Lesion ratio 
T/C x 1002 
NSO3 
4 4 / 5 16 ± 14 100 
6 4 / 5 38 ± 36 100 
8 4 / 5 56 ± 62 100 
10 4 / 5 72 ± 81 100 
12 4 / 5 85 ± 97 100 
ASO-OPN-04 
4 2 / 4* 7 ± 8 44 
6 2 / 4* 9 ± 12 24 
8 2 / 4* 11 ± 18 20 
10 1 / 4* 7 ±13 9 
12 1 / 4* 4.5 ± 9 5 
ASO-BSPII-06 
4 3 / 5 9 ± 8 56 
6 3 / 5 17 ± 17 45 
8 3 / 5 20 ± 22 36 
10 3 / 5 14 ± 17 19 
12 2 / 5* 12 ± 18* 14 
1 Product of pixel number and mean black intensity (±SD) in individual rats as determined by image 
analysis from the X-ray radiograph.  
2 Mean lesion size of treated over control rats x100.  
*Statistically significant vs. control group (χ2 test), p < 0.01.  
3 Nonsense oligonucleotide (NSO) were used as control group. 
Table 10. Inhibition of metastatic bone lysis by OPN and BSPII antisenses delivered by 
nanoparticles. 
It may be concluded that ASO delivery by NP is a promising therapeutic modality 
providing stability of the encapsulated ASOs and a sustained release. These drugs differ 
from small-molecule pharmaceuticals in that instead of binding to a pocket of the protein to 
block certain activities, they prevent the protein from being expressed altogether. This 
minimizes side effects, and increases the effectiveness of the drug. 
8. Refined method for tumor cell application and – detection 
The basic procedures used for anesthesia and tumor cell implantation were as described 
above (see chapter 2) except for the following aspects: 
Subsequently to preparing the femoral artery as well as their related arteries (saphenous 
artery, popliteal artery, descending genicular artery, superficial epigastric artery), they were 
freed from the surrounding fat tissue and mobilized (Fig. 8a, b). 
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Fig. 8a. Region prepared for tumor cell implantation. 
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Fig. 8b. Mobilized arterial branches. 
www.intechopen.com
 Breast Cancer – Current and Alternative Therapeutic Modalities 
 
482 
Then the femoral artery was separated from the neighboring vein and -nerve in the area in 
which the saphenous and superficial epigastric arteries branch off the femoral artery. These 
vessels were exposed to a 1% papaverin solution to inhibit their contraction. After an 
incubation time of one minute, the femoral artery as well as the saphenous and popliteal 
arteries were temporarily occluded by ligating them with three surgical threads (Prolene 7-0, 
Ethicon) (Fig. 9). 
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Fig. 9. Arterial branches prepared for tumor cell injection. 
This enabled to control the blood flow as well as the direction of inoculated tumor cells. To 
that purpose a cannula (27G x ½") was inserted into the dilated lumen of the saphenous 
artery. Due to the persisting blockade of the femoral and saphenous arteries the tumor cells 
(1x105 cells in 0.2 ml PBS) and the blood stream were directed only into the popliteal artery 
(Fig. 10a, b). 
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Fig. 10. a. Placement of the cannula into the saphenous arterty, b. Puncture site after 
withdrawal of the cannula. 
For better visualization, trypan blue was injected to demonstrate the successful direction of 
the injected volume by the colored vessel walls (Fig. 11 a). After withdrawal of the cannula, 
the perforation of the arterial wall was sealed by using a piece of fat tissue which was 
pressed on the puncture site by sterile cotton swabs until the bleeding halted (Fig. 11. b). 
Subsequently, the operation site was closed as described above.  
 
Fat 
tissue
 
Fig. 11. a. Colored vessel walls show the direction of the blood stream, b. the puncture site 
has been closed by fat tissue. 
Advantage of the refined method for tumor cell application.  
The refined method allows to re-use the same artery after tumor cell injection, e.g. for locally 
administering therapeutics. In addition, it qualifies by a smaller surgical wound and a 
reduced time required for the surgical procedure. 
Both methods result in the loco-regional application of tumor cells causing local tumor 
growth, only. The resulting osteolytic lesions caused in femur, tibia and fibula of the 
corresponding hind leg can be monitored by CT as early as two to four weeks after tumor 
cell implantation. In addition, the soft tissue tumor can be recorded by MRT for lesions ≥ 1 
mm3 (corresponding to 1 x 106 tumor cells). The need to observe disease progression of 
tumor cells in animal models has led to the development of various imaging techniques. 
For monitoring the state of tumor cells directly after their intra-femoral application, the 
tumor cells have been stably transfected with the reporter genes (firefly-) luciferase and 
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(cherry-) RFP. The luciferase marker gene allows a non-invasive detection of tumor cells 
down to 1 x 103 tumor cells per hind leg (Fig. 12 a, b). 
The intraperitoneal injection of luciferin (500 µl of a potassium-D-luciferin solution 
(1.5mg/rat)) results in a light emission which can be detected by a sensitive CCD camera 
(IVIS Imaging System – Series 100).  
 
  
 
 
 
 
 
 
Fig. 12. a. 10 Minutes after implantation of 1 x 105 tumor cells and injection of 1.5 mg 
luciferin, b. 60 Minutes after implantation of 1 x 105 tumor cells and re-injection of 1.5 mg 
luciferin. 
Bioluminescence Imaging (BLI) is an extremely sensitive method for detecting metastases. 
Already micro-metastatic signals from a few thousand luciferase positive MDA-MB-
231RFP/Luci+ cells were detectable. However, a crucial drawback of the bioluminescence 
method is the relatively poor spatial resolution and the fact that luciferase-transfected cells 
are indispensably needed. A comparison of the three methods for cell monitoring and their 
sensitivities is given in Figure 13. 
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Fig. 13. Comparison of three different methods for monitoring lytic lesions of an untreated 
control rat. 
CT: Bone lesions were detected two weeks after tumor cell injection. Owing to contrast, bone 
can be differentiated from soft tissues like muscles or fat. As for MRT, a three dimensional 
reconstruction can be generated. However, there is exposure to radiation and this technique 
as well as MRT is distinctly more complex and expensive than BLI.  
MRT: One advantage of this method is the possibility to measure the volume of the lesions. 
Another advantage is related to the high contrast found for soft tissues, including their 
pathologic alterations. This is due to an extremely high resolution.  
BLI: As soon as one week after inoculation the MDA-MB231-cells were detected by light 
emission in response to luciferin administration. With time, the signal increased in size 
regarding the emitting area as well as its intensity. BLI was the most sensitive method for 
detecting bone metastases. 
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